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Adolescent PrEP Administration: An Education Curriculum for Providers
Introduction
On May 15, 2018, the Federal Drug Administration (FDA) approved once daily
tenofovir/emtricitabine (TDF/FTC) for use as preexposure prophylaxis (PrEP) for adolescents
(weighing greater than 35kgs) engaging in high-risk sexual behavior (Gilead, 2018). This
decision was largely based on the Adolescent Medicine Trials Network for HIV/AIDS
Interventions (ATN) 113 which demonstrated that PrEP was well tolerated among the
adolescents, age 15-17, enrolled in the study (Hosek, 2017). The use of TDF/FTC for PrEP in
adults (18 and older) was approved by the FDA in 2012 after its safety and efficacy had been
demonstrated in multiple international clinical trials (FDA, 2016). Iniciativa Profilaxis PreExposición (iPrEx), Partners PrEP, and Pre-exposure Option for Reducing HIV in the UK:
Immediate or Deferred (PROUD) demonstrated that if taken daily, PrEP is at least 92% effective
in preventing HIV transmission among men and transgender women who have sex with men and
sero-discordant couples (Baeten, 2016; Grant, 2010; McCormack, 2016).
Since 2012, there has been mounting pressure from the adolescent health community to
make PrEP accessible to individuals under 18 years of age (Burda, 2015). The Centers for
Disease Control and Prevention (CDC) reported that in 2016, youth aged 13 to 24 accounted for
21% of all new HIV diagnoses in the United States (Hess et al, 2017). In New York City in 2016,
there were 882 new HIV diagnoses among individuals 13 to 29 years of age, out of a total of
2279 new infections (39%). Seventy-nine of those new diagnoses were among individuals aged
13-19 years of age. Since the majority of HIV infections occur among individuals between the
ages of 20 and 29 years, health care providers need to consider educating patients about HIV
prevention and provide biomedical interventions prior to the patient’s 20th birthday (HIV
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Epidemiology and Field Services Program, 2017) (Ocfemia, 2018). Additionally, adolescents,
especially minors, take many sexual risks in pursuit of autonomy and self-exploration with
concurrent poorly developed impulse control (Steinberg, 2009). It is clear that adolescents are, at
least, as much in need of PrEP as individuals of other age groups.
Adolescent Provider PrEP Knowledge and Attitudes
In a recent sample of 162 surveyed adolescent providers, 93.2% of the providers had
heard of PrEP, however, only 35.2% of these providers indicated that they had previously ever
prescribed PrEP. Sixty-five percent of the providers surveyed stated that they were “willing to
prescribe PrEP to adolescents ages 13-17” and this indicator was associated with the provider
having enough knowledge to safely provide PrEP to adolescents (Hart-Cooper, 2018, p243).
Mullins and colleagues conducted a mixed method study that included 56 clinicians within the
Adolescent Clinical Trials Network (ATN) who provided care to HIV positive adolescents, and
their attitudes towards providing PrEP to at-risk HIV uninfected adolescents (Mullins, 2017).
The primary outcomes of the study included 1) intention to provide PrEP to at-risk adults over 18
years of age and at-risk adolescents under 18 years of age and 2) actual prescriptions to adults
and adolescents in at-risk groups. Significantly more clinicians had prescribed PrEP to adult men
who have sex with men (MSM) than to adolescent MSM. The authors found that clinicians
identified two significant barriers to prescribing PrEP to adolescents: the perceived need for a
multidisciplinary team and inclusion of behavioral interventions in the visit. These results
suggested that even providers who were knowledgeable about PrEP needed a “brief, streamlined
and effective behavioral intervention that can be delivered with PrEP” (Mullins, 2017, p514).
Similar findings were presented in a study of examining perceived barriers and
facilitators to prescribing PrEP among Boston HIV care providers caring for adults. While the
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majority of providers understood PrEP to be efficacious, they expressed desire for readily
accessible, simple guidance regarding the provision of PrEP that would not require significant
time and effort (Krakower, 2014).
In 2017, a web-based survey among pediatric (n=35) and internal medicine providers at a
large urban medical center in Upper Manhattan revealed that although pediatric providers
reported taking a sexual history on majority (68.5%) of their patients above the age of 13, only
14% of these providers felt comfortable assessing these patients’ eligibility for PrEP. A
consistent barrier to providing PrEP across all groups of providers was lack of formal training
(Zucker et al, 2018).
The FDA approval of an adolescent indication for PrEP, removed an important barrier to
providing PrEP to adolescents nationwide. With this development, the priority now shifts to
considering implementation challenges, opportunities, and determinants of success. This calls for
setting educational standards for providers, establishing PrEP guidelines specific to adolescents,
offering support for providers prescribing PrEP to adolescents or information regarding referrals
should adolescent providers need to outsource the provision of PrEP for their patients.
To respond to these challenges, we undertook the development of an evidence-based
curriculum for the purpose of training healthcare practitioners how to provide HIV prevention
interventions, including PrEP, to an adolescent population.
Methods
A comprehensive provider curriculum was developed focused on adolescent-specific
issues related to PrEP screening and monitoring. A literature review was conducted to identify
learning needs of adolescent providers, identify key domains and to design the curriculum. The
articles were retrieved from medical, public health, nursing and adolescent health journals via
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PubMed and SCOPUS. The search terms used were HIV Prevention, Pre-Exposure Prophylaxis,
Healthcare Provider, Implementation, Adolescent Health and Primary Care. Medical/Nursing
education and adult learning guides were used in the development of the curriculum (Brenner,
2010; Diamond, 1998; Joyce, 2002).
The Adolescent HIV Prevention Curriculum was piloted on September 21st 2017 during
one day training session. The purpose of this pilot was to construct the flow of the curriculum
and obtain feedback about the content.
An expert panel made up of both nursing/medical professionals and public health
officials was contacted to review the curriculum to determine content validity (FIGURE ONE).
The seven experts are leaders in the field of HIV Prevention, Adolescent Health and
Medical/Nursing Education. They were asked to review the content of the curriculum and
evaluate for importance, clarity and relevance. To determine scale-level content validity, a threepoint scale was constructed (ie: 1=not relevant, 2=somewhat relevant, 3=very relevant). A
ratings guide was developed through Qualtrics (Provo, UT), and the experts were asked to log
their responses electronically. An expert selecting “somewhat relevant” or “somewhat clear” for
a reviewed section was categorized as an affirmative. All sections that received a 78%
affirmative response were deemed valid (Polit, 2007).
Results
Curriculum Content
Eight domains were identified as essential for inclusion in the curriculum: 1) What is
PrEP/PEP?, 2) Overview of PrEP Efficacy- Clinical Trials, 3) PrEP Eligibility, 4) PEP
Eligibility, 5) Sexual History Taking in the PrEP Era, 6) Can Adolescents Access PrEP?, 7) How
to conduct an Adolescent PrEP Medical Visit and 8) Benefits and Insurance Navigation.
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The curriculum starts with a comprehensive overview of the PrEP efficacy clinical trials
and reviews of some of the real-world demonstration projects indicating PrEP’s effectiveness. It
is recommended that clinicians receive an overview of the published PrEP clinical trials and
demonstration projects which will provide context to questions that may arise with patients or
their caretakers. Having ready access to comprehensive yet concise data supporting the safety,
efficacy and tolerability of PrEP both in research and real-world settings is important for any
clinician prescribing PrEP.
Additionally, this curriculum includes an in-depth look at how to assess if a patient is a
candidate for HIV prevention biomedical interventions. In the United States, HIV risk varies
based on location as well as age; the curriculum encourages providers to develop a thoughtful
and individualized approach in their practice that incorporates the CDC and local department of
health guidelines but, importantly, also includes careful behavioral screening of patients they
serve as well as examination of local HIV and Sexually Transmitted Infection (STI) incidence
rates. Instruction on how to assess for prospective risk, especially when working with
adolescents, is included. The adolescent in front of a clinician may answer no to every question
about historic risk behaviors but over the next year, may begin to explore their sexuality through
engaging in risky sex.
The final curriculum includes tips on how to conduct an adolescent PrEP focused sexual
history by expanding on the CDC’s 5Ps (CDC, 2005) (FIGURE TWO). The algorithm guides
providers through questions that could be important in establishing a patient’s risk profile. When
initiating a PrEP focused sexual history, we recommend starting with “what is your ideal sex
life”. This helps to establish with the adolescent patient that they can feel free to discuss with the
provider what they imagine their sex life to be like once they start PrEP. It not only gives the
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provider insight into what patient’s desires are, but also sets a positive and optimistic tone for the
visit. Conducting the sexual history in a sex-positive manner increases patient comfort and will
ultimately lead to better retention.
We also recommend including a brief self-administered sexual history as part of the
adolescent clinic visit. This is not designed to replace a comprehensive sexual history but as an
opportunity for the adolescent to reveal behaviors that they may not feel comfortable revealing to
a provider or coordinator.
A key component of the curriculum was a development of a detailed checklist of
evaluations conducted at each visit as well as visit schedule (FIGURE THREE). The aim is to
provide guidance on how to conduct a PrEP visit within the time constraints of the clinic setting.
Our graphic, adapted from New York State Department of Health AIDS Institute guidelines
(New York State AIDS Institute, 2018) provides a quick overview of the visit components
separated by areas or tasks (labs, psychosocial evaluation, next steps) to encourage task sharing
between providers and PrEP navigator/coordinator or social worker in order to create efficiencies
and save time. Due to the increasing incidence of sexually transmitted infections (STIs),
especially in New York City (CDC, 2017; NYC, 2017), we recommend testing for STIs at every
PrEP visit, including the one month follow up. Not only does this offer an opportunity to test a
cure if there is an STI diagnosis at the first visit, but it can have the beneficial effect of
normalizing three-site STI testing for patients. We also recommend self-collection
gonorrhea/chlamydia testing when possible (Taylor, 2013).
Curriculum Pilot
The curriculum was tested during a 2-day training of 54 staff from eight high-school
based health clinics. Staff members consisted of 14 healthcare providers, social workers,
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registered nurses, medical assistants, health educators and the clinics’ front desk staff. In a posttraining assessment, the majority of providers found the content helpful but wished the
curriculum included more training on how to conduct a PrEP-focused sexual history. The
providers stated that, although they had been working in the field of adolescent health for some
time, their sexual histories typically focused more on family planning concerns and they stated
that very rarely did they have young MSM seeking services in their school-based clinics. Based
on this feedback, a PrEP-focused sexual history was added to the final curriculum prior to expert
panel review.
Expert Panel Review
There was 100% agreement among all seven experts in the relevance and importance of
each of these sections in the curriculum. One expert indicated that the section entitled “Overview
of PrEP Efficacy” was unclear but the overall affirmative response rate for this section was
greater than 78% indicating its validity (TABLE ONE)
The experts unanimously agreed that the content was appropriate for a professionally
diverse audience.
Discussion
A comprehensive curriculum on the provision of HIV prevention modalities to
adolescents has been successfully developed, piloted, and validated by a panel of experts. While
the provision of PrEP can be as simple as writing a prescription, more is needed to engage and
assess an adolescent in order to administer a multicomponent HIV prevention intervention. This
curriculum contains content validated components that should be included when training
clinicians how to administer PrEP to adolescents. It has been shown that certain misconceptions
regarding PrEP efficacy, for example, have led providers away from prescribing PrEP to their
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patients (Silapaswan, 2017). While recognizing this, our curriculum seeks to shape providers
attitudes regarding integrating PrEP into their adolescent health practices by initially describing
the efficacy trials. We then give providers the concrete skills needed to implement a PrEP
assessment, PrEP initiation and the PrEP follow up.
Adherence to PrEP is critical to its efficacy and it undoubtedly will be what adolescents
struggle with the most (Grant, 2014) (Hoesk, 2016). Healthcare providers planning to provide
PrEP to adolescents must incorporate adherence assessments into their routine care. These
assessments do not necessarily have to be completed by a healthcare provider but must be
included in routine visits to ensure quality care. We recommend that if adherence concerns arise,
the adolescent patient should return to clinic monthly for evaluation and only receive 30 days of
medication at a time to ensure there has been no HIV seroconversion. The development and
implementation of methods to track and support adherence using technology-based tools that
appeal to adolescents, are under way in a variety of settings (Koss, 2017; Fuch, 2018; HightowWeidman, 2017).
Toxicities related to PrEP such as renal function decline and bone mineral density (BMD)
loss are rare although particularly worrisome in an adolescent population. Providers need to
understand the nature of these toxicities when prescribing PrEP therefore inclusion of these
topics in the training is crucial (Hosek, 2017). In our curriculum, we educate providers on the
clinical trials examining bone mineral density loss and renal function decline with the
understanding that more research is needed in a younger population.
Finally, as previously mentioned, one of clinicians’ concerns with providing PrEP to
adolescents is navigating how the adolescent can ultimately receive the medication (Mullins,
2017). Insurance coverage and the concern of parental involvement is a prohibitory barrier for
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adolescents receiving PrEP. It becomes very important for clinicians to understand how their
adolescent patients can receive PrEP beyond simply writing the prescription. Education and
training about the resources available to cover provision of PrEP to adolescents is critically
important to retention. Our curriculum provides healthcare providers with strategies in
navigating payment for PrEP in an adolescent community although this may vary at state and
local levels.
Consensus from the expert panel supports the dissemination of this Adolescent PrEP
Curriculum. It is recommended that when training clinicians on the provision of PrEP to
adolescents that all eight domains presented in this curriculum be included.
A limitation of this paper is a smaller sized expert panel of seven experts. Further
quantitative evaluation of the curriculum’s effectiveness is needed through implementation and
pre/post testing. These efforts are underway. Additionally, content needs to be developed on how
best to engage the parents of adolescents in the administration of PrEP. Another limitation of our
curriculum is the lack of supporting data associated with same-day PrEP starts, which we
recommend in the visit schedule. New York City Department of Health and other health
departments have recommended starting PrEP at the initial visit as a way of avoiding potential
barriers that may arise in the follow up to a prescription (NYC, 2014)(Kamis, 2018). There have
been arguments that starting PrEP on the same day as the first visit without having access to HIV
negative confirmatory test result can overlook a potential acute HIV infection and therefore lead
to the chance of a resistant HIV virus. Experts have estimated that resistance to TDF/FTC while
on PrEP can develop within 15-540 days and in the presence of an acute HIV infection would
only occur in approximately 25% of the infections (Dimitrov, 2016)(Lehman, 2015). We contend
that same-day PrEP starts are effective in ensuring patients initiate PrEP and we also conduct a
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repeat HIV test at the one month visit as a failsafe to catch any possible acute HIV infections.
More research regarding retention outcomes is necessary on this topic.
Conclusion
We have learned a great deal in the first 6 years of PrEP implementation in the United
States, and this can be applied to the roll out of PrEP for adolescents. However, adolescents have
a unique set of needs when it comes to a biomedical intervention for HIV prevention. The
healthcare community, for the first time, has an intervention that can prevent the transmission of
HIV among at-risk individuals if taken correctly. Given the high rates of HIV in the younger age
groups, we have a considerable responsibility to determine how to efficiently and safely provide
this intervention to youth. PrEP Implementation in a younger population requires a new set of
youth focused guidelines, teaching points, and educational methodologies. The validated
curriculum developed through the stakeholder driven process may be an important contribution.
Preventing HIV transmission in adolescents is a national and international priority and is
undoubtedly an essential step necessary to end the HIV epidemic.
To access our validated curriculum, please use the following link
prevention.nyc/learn/adolescent-prep/
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